We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





RT-LAMP Assay Developed for SARS-CoV-2

By LabMedica International staff writers
Posted on 20 Apr 2020
SARS-CoV-2 is the causative viral pathogen of COVID-19, and diagnosis of COVID-19 can be done through CT scan of suspicious patients and a confirmatory laboratory test is performed using published real-time quantitative polymerase chain reaction (RT-qPCR) methods. More...


Although RT-qPCR methods are used as the gold-standard for detection of pathogens due to its high sensitivity and specificity, it still have some caveats. To overcome any restriction of RT-qPCR and still detect pathogens’ nucleic acids, isothermal amplification methods have been developed. Among such methods, Loop-mediated isothermal amplification (LAMP) method has some advantages to be applied for point-of-care test (POCT). Well optimized LAMP assay shows sensitivity comparable to that of PCR, less than 10 copies per reaction.

Scientists at the Korea Research Institute of Chemical Technology (Daejeon, Republic of Korea) and their colleagues developed and evaluated RT-LAMP assays to detect genomic RNA of SARS-CoV-2. The team used SARS-CoV-2 viral RNA that was prepared as previously described. hCoV-229E and hCoV-OC43 viral RNA were isolated from culture media of infected MRC-5 cells and MERS-CoV RNA was isolated from cell pellet lysate of infected Vero cells. To evaluate genomic copy number of viral RNAs, dilutions of standard RNAs and viral RNAs in TE buffer were subjected to one-step RT-qPCR. RT-qPCR reactions were carried out using a LightCycler 96 instrument (Roche Molecular Systems, Inc, Pleasanton, CA, USA).

The team reported that RT-LAMP assays used in their study can detect as low as 100 copies of SARS-CoV-2 RNA. Five out of seven primer sets showed specific amplification for at least one replicate of duplicate with cDNA concentration corresponding to 1.7 x 101 copies of input RNA. Cross-reactivity of RT-LAMP assays to other human Coronaviruses was not observed. The lauco crystal violet (LCV) method was applied to achieve colorimetric detection of LAMP reaction for their RT-LAMP assay so that the tests potentially performed in higher throughput.

The authors concluded that they have developed highly specific RT-LAMP assays for detection of SARS-CoV-2. The results of these RT-LAMP assays can be detected within 30 minutes after amplification reaction began. In addition, they provided optimized reaction conditions to which LCV colorimetric detection method is applied that can be used for point-of-care tests. The study was published on April 7, 2020 in The Journal of Molecular Diagnostics.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.